Liver Cirrhosis: From Pathophysiology to Disease Management

List of principal contributors List of chairpersons SECTION I: PATHOMECHANISMS OF FIBROGENESIS (1): INITIATION.- 1 Apoptosis and oncotic necrosis: profibrotic signalling mechanisms of cell death.- 2 The mucosal immune system in the pathogenesis of liver disease.- 3 Immune responses in hepatitis C virus infection.- 4 Inflammatory pathways in liver homeostasis and liver injury.- SECTION II: PATHOMECHANISMS OF FIBROGENESIS (2): MEDIATORS.- 5 A complex network of intra- and intercellular mediators regulate cellular activation and transdifferentiation of hepatic stellate cells.- 6 Genetic determinants of liver fibrogenesis: a systems genetics approach in recombinant inbred mice.- 7 Molecular mechanisms of fibrosis progression in non-alcoholic steatohepatitis (NASH).- 8 New role of bile acid metabolism in intestinal bacteria translocation.- SECTION III: CELLULAR RESPONSES TO CHRONIC LIVER INJURY.- 9 The hepatic stellate cell: a progenitor cell.- 10 Role of non-parenchymal cells in portal hypertension.- 11 Role of angiogenesis in portal hypertension.- 12 Current concept of hepatic fibrogenesis in mouse models of liver fibrosis.- 13 Hepatic fibrogenesis and carcinogenesis: Kru¨ppel-like factors and beyond.- SECTION IV: CLINICAL MANAGEMENT OF PROGRESSIVE LIVER FIBROSIS.- 14 Biomarkers of liver fibrosis.- 15 Clinical evaluation of disease progression in chronic liver disease: towards an integrated system?.- 16 Fibrosis regression and innovative antifibrotic therapies: from bench to bedside.- SECTION V: CLINICAL MANAGEMENT OF PORTAL HYPERTENSION (1): PREPRIMARY AND PRIMARY PROPHYLAXIS.- 17 Dynamic increase of intrahepatic vascular resistance in cirrhosis.- 18 Remodelling portal hypertension: preprimary prophylaxis.- 19 When and how to scope in portal hypertension.- 20 Prevention of first variceal bleeding.- SECTION VI: CLINICAL MANAGEMENT OF PORTAL HYPERTENSION (2): COMPLICATIONS OF CIRRHOSIS.- 21 Therapy of acute.- 23 From sodium retention to refractory ascites: the role of new drugs.- 24 Transjugular intrahepatic portosystemic shunt versus paracentesis: a critical review of randomized studies and meta-analyses.- 25 Spontaneous bacterial peritonitis, a disease of the gut? Therapeutic implications.- 26 Hepatorenal syndrome -- a defined entity with a standard treatment?.- 27 From infections to hepatic encephalopathy.- 28.- Liver and lung -- treatment of hepatopulmonary diseases.- 29 Allocation in adult liver transplantation: is the Model for Endstage Liver Disease the solution? North American perspective.- 30 Emerging future therapies for portal hypertension.- Index